失智症治疗市场 - 按药物类别（胆碱酯酶、NMDA 受体、谷氨酸、组合药物、MOA）、适应症（阿兹海默症、帕金森氏症、血管、FTD）、给药途径、配销通路与预测，2024 年 - 2032 年

在政府不断采取的措施和技术创新的带动下，痴呆症治疗市场规模预计从 2024 年到 2032 年将以 7.6% 的复合年增长率扩大。最近，世界各地许多政府都在投资研发以提供补助金并加快新疗法的审批流程。这种支持正在促进早期诊断、个人化治疗和改进护理方法的进步。

此外，人工智慧驱动的诊断和先进的药物输送系统等技术创新正在改变痴呆症护理，以提高患者的生活品质并减轻护理人员的负担。例如，2023年5月，美国FDA宣布补充核准Rexulti（brexpiprmaze）用于治疗阿兹海默症的躁动。这标誌着 FDA 批准的第一个针对这种特定痴呆相关症状的治疗方法的推出。

整个市场分为药物类别、适应症、给药途径、配销通路和地区。

根据药物类别，从2024 年到2032 年，谷氨酸抑制剂领域的痴呆症治疗市场价值预计将大幅增长，因为它们能够靶向神经递质谷氨酸，而谷氨酸在神经退化性疾病中可能过度活跃。透过减少谷氨酸的过度活性，这些抑制剂可以保护脑细胞免受损伤并改善认知功能。研究人员也正在探索这些抑制剂来帮助控制症状并可能减缓疾病进展。

由于越来越需要为痴呆症患者提供更有针对性和可管理的解决方案，预计到 2032 年，注射给药途径的痴呆症治疗行业份额将大幅增长。研究人员正在开发和测试各种注射药物，以更有效地针对失智症的根本原因和症状。一些治疗方法还旨在将药物直接输送到血液或神经系统中，以提高疗效并最大限度地减少副作用。

从区域来看，由于人口老化和公众意识宣传活动的不断加强，欧洲痴呆症治疗市场规模预计将在 2024 年至 2032 年间强劲增长。随着该地区老年人数量的不断增加，对有效的痴呆症护理解决方案的需求不断增加。公众意识活动正在对人们进行有关痴呆症的教育，以鼓励早期诊断并支持新疗法的研究，从而促进欧洲的行业成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 痴呆症盛行率增加
    • 越来越重视早期诊断和干预
    • 诊断和治疗方法的技术进步
  • 产业陷阱与挑战
    • 药物研发成本高
    • 临床试验失败率高
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析
• 未来市场趋势

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 胆碱酯酶抑制剂
• NMDA受体拮抗剂
• 组合药物
• 谷氨酸抑制剂
• 单胺氧化酶抑制剂
• 其他药物类别

第 6 章：市场估计与预测：按指标划分，2021 - 2032 年

• 主要趋势
• 阿兹海默症
• 帕金森氏症痴呆
• 血管性失智症
• 路易氏体失智症
• 额颞叶失智症（FTD）
• 其他适应症

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
• 口服
• 可注射
• 透皮贴剂

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• AbbVie Inc.
• Biogen
• Cipla Inc.
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• Merck & Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.

Dementia Treatment Market size is projected to expand at 7.6% CAGR from 2024 to 2032, led by the rising government initiatives alongside technological innovations. Lately, numerous governments worldwide are investing in R&D for providing grants and expedite the approval process for new therapies. This support is fostering advancements in early diagnosis, personalized treatment, and improved care methods.

Moreover, technological innovations, such as AI-driven diagnostics and advanced drug delivery systems are transforming dementia care to enhance the quality of life for patients and reduce the burden on caregivers. For instance, in May 2023, the U.S. FDA announced the supplemental approval of Rexulti (brexpiprazole) for treating agitation in Alzheimer's disease. This marked the introduction of the first FDA-approved treatment for this specific dementia-related symptom.

The overall market is segregated into drug class, indication, route of administration, distribution channel, and region.

Based on drug class, the dementia treatment market value from the glutamate inhibitors segment is estimated to rise at a significant rate from 2024 to 2032 due to their ability to target the neurotransmitter glutamate which can be overly active in neurodegenerative conditions. By reducing the excessive activity of glutamate, these inhibitors protect brain cells from damage and improve cognitive function. Researchers are also exploring these inhibitors to help manage symptoms and potentially slow the disease progression.

Dementia treatment industry share from the injectable route of administration segment is anticipated to expand at a substantial growth rate up to 2032, owing to the rising need for offering more targeted and manageable solutions to those living with dementia. Researchers are developing and testing various injectable medications to target underlying causes and symptoms of dementia more effectively. Several treatments are also designed to deliver drugs directly into the bloodstream or nervous system to improve efficacy and minimize side effects.

Regionally, the Europe dementia treatment market size is projected to witness robust growth between 2024 and 2032, on account of the aging population and increasing public awareness campaigns. As the number of elderly individuals is growing in the region, there is rising demand for effective dementia care solutions. Public awareness campaigns are educating people about dementia for encouraging early diagnosis and support research into new treatments, adding to the industry growth in Europe.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of dementia
    • 3.2.1.2 Growing emphasis on early diagnosis and intervention
    • 3.2.1.3 Technological advancements in diagnosis and treatment methods
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of drug development
    • 3.2.2.2 High failure rate in clinical trials
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Cholinesterase inhibitors
• 5.3 NMDA receptor antagonist
• 5.4 Combination drugs
• 5.5 Glutamate inhibitors
• 5.6 MAO inhibitors
• 5.7 Other drug classes

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Alzheimer's disease
• 6.3 Parkinson disease dementia
• 6.4 Vascular dementia
• 6.5 Lewy body dementia
• 6.6 Frontotemporal dementia (FTD)
• 6.7 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable
• 7.4 Transdermal patch

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacy
• 8.3 Retail pharmacy
• 8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Biogen
• 10.3 Cipla Inc.
• 10.4 Daiichi Sankyo Company, Limited
• 10.5 Eisai Co., Ltd.
• 10.6 Eli Lilly and Company
• 10.7 Merck & Co., Inc.
• 10.8 Novartis AG
• 10.9 Otsuka Pharmaceutical Co., Ltd.
• 10.10 Sun Pharmaceutical Industries Ltd.